Product fact sheet
Ther-Biotic S. boulardii: 3 Billion CFU & Strain-Identity Gap
Ther-Biotic Saccharomyces boulardii provides 3 billion CFU per capsule, but the current US label does not disclose a strain code, limiting trial-level evidence matching.
A simple 3-billion-CFU S. boulardii capsule from the Klaire Labs/Ther-Biotic line. The important limitation is that SFI does not identify a strain on the current page, so evidence for CNCM I-745 or another named S. boulardii strain should not be treated as proof for this product.
People whose clinician specifically wants this Klaire/SFI product and understands the species-versus-strain limitation, Users comparing low-complexity yeast probiotic formulas
Anyone trying to buy the exact CNCM I-745 strain studied in Florastor literature, Severely immunocompromised people or people with central venous catheters unless explicitly cleared by their treating team
Key tradeoff: Simple formula and clear CFU amount, but much weaker trial traceability than a strain-identified S. boulardii product.
This is a factual fit-and-tradeoff summary, not a product recommendation. Formula, device and brand claims remain manufacturer claims unless the cited source is explicitly regulatory or independent testing.
Ther-Biotic Saccharomyces boulardii is a simple yeast-probiotic product from the SFI Health/Ther-Biotic line historically associated with Klaire Labs. The current label states 3 billion CFU per capsule.
The most important evidence-mapping fact is what the label does not say: the current US product page does not identify a strain designation.
Why strain identity matters
The American Gastroenterological Association lists S. boulardii among several probiotic options it suggests during antibiotic treatment when the goal is prevention of Clostridioides difficile infection. That is useful professional context, but it does not make every S. boulardii product interchangeable.
For comparison, Florastor identifies its yeast as S. boulardii CNCM I-745. Trials and mechanistic research tied to CNCM I-745 should not be silently assigned to an unidentified S. boulardii strain in another bottle.
This is a recurring problem in probiotic shopping: a familiar species name can create the appearance of evidence equivalence when the actual study used a defined strain.
Formula
The current SFI page lists:
- Saccharomyces boulardii — 3 billion CFU per capsule;
- a simple capsule format;
- no strain code on the current US product page.
That makes the product easy to understand but harder to map precisely to strain-specific research.
When a practitioner-oriented product can still make sense
A clinician may choose a product based on prior experience, tolerability, availability or a specific protocol. That is a legitimate clinical decision. It is different from claiming that the retail product itself has been validated by every study involving the species.
The product is therefore species-identified but strain-unresolved for evidence-mapping purposes.
Safety is not identical for every patient
Live-yeast probiotics deserve extra caution in medically vulnerable people. Published fungemia cases disproportionately involve severe illness and other high-risk settings; central venous catheters and immune compromise are particularly relevant.
People with a yeast allergy should avoid S. boulardii products. People who are critically ill, markedly immunocompromised or have a central venous catheter should not self-start a live-yeast probiotic without the treating team’s approval.
Evidence fit and main limitation
The formula is simple and clearly quantified at 3 billion CFU per capsule. The missing strain designation is the central limitation because it prevents a clean evidence bridge to named S. boulardii strains such as CNCM I-745.
Compare Florastor Dual Action if exact CNCM I-745 identity matters, and Ther-Biotic ABx Support if you are comparing Klaire/SFI formulas designed around antibiotic use.
Formula facts
Ingredients, actives and label details
- Probiotic identity
- Saccharomyces boulardii; strain not disclosed on current product page Basis: Manufacturer Source: Ther-Biotic Saccharomyces boulardii — official product information
- Viable count
- 3 billion CFU per capsule Basis: Manufacturer Source: Ther-Biotic Saccharomyces boulardii — official product information
- Guideline context
- AGA names S. boulardii as one option during antibiotic exposure for C. difficile prevention, but strain and formulation still matter Basis: Professional guideline Source: Role of probiotics in the management of gastrointestinal disorders
- Why strain identity matters
- Florastor identifies CNCM I-745; that strain-specific evidence cannot automatically be transferred to an unidentified S. boulardii strain Basis: Comparative editorial Source: Florastor FAQ — strain, dose and storage information
Source labels preserve provenance. Manufacturer specifications, ingredient lists and performance claims are not treated as independent clinical evidence; regulatory records and independent measurements are identified separately when available.
Safety first
What should make you slow down?
Use the product as directed, avoid treating concentrated wellness products as automatically harmless, and ask a qualified clinician when your situation or medication use makes the decision less routine.
Where to buy
Current tracked merchants
Commerce note: merchant economics never enter our editorial score. Affiliate links are identified as (paid link) and use sponsored-link markup.
No merchant destination is currently tracked for this product.
Source trail
Primary documents and supporting evidence
- Ther-Biotic Saccharomyces boulardii — official product informationSFI Health (Klaire Labs heritage) · Manufacturer · retrieved 2026-08-12
- Role of probiotics in the management of gastrointestinal disordersAmerican Gastroenterological Association · Clinical guideline · retrieved 2026-08-12
- Florastor FAQ — strain, dose and storage informationFlorastor / Biocodex · Manufacturer · retrieved 2026-08-12
- Epidemiology of Saccharomyces fungemia: a systematic reviewMedical Mycology · Systematic review · retrieved 2026-08-12